Cytokinetics, Inc. (CYTK)
62.91
+0.90
(+1.45%)
USD |
NASDAQ |
Oct 09, 16:00
62.92
+0.01
(+0.02%)
Pre-Market: 20:00
Cytokinetics Free Cash Flow (Quarterly) : -164.17M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -164.17M |
| March 31, 2026 | -151.39M |
| December 31, 2025 | -148.30M |
| September 30, 2025 | -116.86M |
| June 30, 2025 | -132.38M |
| March 31, 2025 | -137.28M |
| December 31, 2024 | -66.86M |
| September 30, 2024 | -102.20M |
| June 30, 2024 | -101.23M |
| March 31, 2024 | -129.51M |
| December 31, 2023 | -74.11M |
| September 30, 2023 | -96.42M |
| June 30, 2023 | -122.52M |
| March 31, 2023 | -122.69M |
| December 31, 2022 | -101.40M |
| September 30, 2022 | -87.96M |
| June 30, 2022 | -91.33M |
| March 31, 2022 | -30.16M |
| December 31, 2021 | -62.49M |
| September 30, 2021 | -54.47M |
| June 30, 2021 | -38.29M |
| March 31, 2021 | -36.14M |
| December 31, 2020 | 45.60M |
| September 30, 2020 | 11.78M |
| June 30, 2020 | -28.30M |
| Date | Value |
|---|---|
| March 31, 2020 | -31.18M |
| December 31, 2019 | -20.36M |
| September 30, 2019 | -21.27M |
| June 30, 2019 | -24.73M |
| March 31, 2019 | -27.16M |
| December 31, 2018 | -12.54M |
| September 30, 2018 | -32.59M |
| June 30, 2018 | -26.91M |
| March 31, 2018 | -30.07M |
| December 31, 2017 | -24.85M |
| September 30, 2017 | -25.93M |
| June 30, 2017 | -31.52M |
| March 31, 2017 | -22.33M |
| December 31, 2016 | 76.98M |
| September 30, 2016 | -12.43M |
| June 30, 2016 | -11.23M |
| March 31, 2016 | -17.93M |
| December 31, 2015 | -10.15M |
| September 30, 2015 | -10.40M |
| June 30, 2015 | -9.362M |
| March 31, 2015 | 34.23M |
| December 31, 2014 | -8.377M |
| September 30, 2014 | -9.615M |
| June 30, 2014 | -9.80M |
| March 31, 2014 | -18.16M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Bristol Myers Squibb Co. | 3.088B |
| Alnylam Pharmaceuticals, Inc. | 292.04M |
| BioMarin Pharmaceutical, Inc. | 133.86M |
| Exelixis, Inc. | 300.92M |
| Ionis Pharmaceuticals, Inc. | 547.30M |